Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...
The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...
Among other functions, the NK cells (natural killers, a type of lymphocyte forming part of the immune system) have the capacity to detect and eliminate cancer cells. But in some cases they cannot ...
Lu-RAD 204 For The Treatment Of Patients with Metastatic Solid Tumors With PD-L1 Expression ... 30% of gastric cancers are classified to be HER2 positive [+]. The company burns roughly US$19.8 ...
News-Medical.Net on MSN7d
Researchers develop tool to enhance NK cells against cancerA team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells ...
Patients with certain subtypes of breast cancer may face a higher risk of death from the cancer if they wait more than 42 ...
In June 2024, Jiangsu Alphamab entered into a research and collaboration agreement with ArriVent BioPharma, Inc. to use Jiangsu Alphamab's proprietary linker-payload (Alphatecan) and glycan-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback